Clinical Trial Detail

NCT ID NCT02816021
Title Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

Azacitidine + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.